Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rincón, S. Articles by Espinel-Ingroff, A. Search for Related Content PubMed PubMed Citation Articles by Rincón, S. Articles by Espinel-Ingroff, A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2006, p. 3429-3431, Vol. 44, No. 9
0095-1137/06/$08.00+0     doi:10.1128/JCM.00989-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

A Modified Christensen's Urea and CLSI Broth Microdilution Method for Testing Susceptibilities of Six Malassezia Species to Voriconazole, Itraconazole, and Ketoconazole

S. Rincón,¹ M. C. Cepero de García,¹ and A. Espinel-Ingroff^2*

Centro De Investigaciones Microbiológicas CIMIC, Universidad de los Andes, Bogotá, Colombia,¹ VCU Medical Center, Richmond, Virginia 23298-0049²

Received 11 May 2006/ Returned for modification 19 June 2006/ Accepted 3 July 2006

Top Abstract Text References

 
Two supplemented broths (Christensen's urea with 0.1% Tween 80 and 0.5% Tween 40 and RPMI 1640 with 1% glycerol, 1% peptone, 1.8% glucose, and 0.05% Tween 80) were evaluated to determine voriconazole, itraconazole, and ketoconazole MICs for 200 Malassezia sp. isolates. Malassezia globosa and M. restricta were the least susceptible species (MICs at which 90% of the isolates tested were inhibited, 1 to 8 µg/ml versus 0.25 to 1 µg/ml).

Top Abstract Text References

 
An increased incidence of severe dermatological and systemic infections by Malassezia spp. has been reported among immunosuppressed patients. Standardized assays are not available to determine the in vitro susceptibilities of these yeasts to any antifungal due to their complex nutritional requirements. Recently, Christensen's urea (measures metabolic activity) and supplemented RPMI 1640 (measures growth inhibition) broths were evaluated (16, 21). We investigated (i) several medium formulations, (ii) inoculum preparations, and (iii) incubation times of modified urea and Clinical and Laboratory Standards Institute (CLSI) broth microdilution techniques to determine voriconazole, itraconazole, and ketoconazole MICs for 200 isolates (74 Malassezia globosa, 50 M. sympodialis, 52 M. furfur, 16 M. restricta, 6 M. obtusa, and 2 M. pachydermatis).

The 200 isolates were cultured from 77 patients (human immunodeficiency virus positive and negative) with dermatological pathologies (3) and 33 healthy volunteers. Isolates were identified by following conventional standard guidelines (10, 11, 15). Six reference Malassezia strains (see Table 2), CLSI quality control strain Candida krusei ATCC 6258 (2, 17), and Cryptococcus neoformans ATCC 90112 were tested as controls. The identification of representative isolates of each species and of the six reference isolates was confirmed by PCR-restriction fragment length polymorphism (8). For the quality control strain, the MICs of the three azoles were within the expected ranges (2, 17).

View this table: [in this window] [in a new window]

TABLE 2. In vitro susceptibilities of reference type Malassezia isolates to three antifungal agents as determined by the modified urea and CLSI broth microdilution methodsa

CLSI RPMI 1640 medium (17) is not suitable for most Malassezia spp.; it lacks the lipid supplements required for their growth. In this study, the evaluation of nine RPMI 1640 medium (Sigma, St. Louis, MO) formulations with the reference isolate of each species (M. furfur, M. globosa, M. restricta, M. sympodialis, M. pachydermatis, and M. obtusa) indicated that no. 7 (Table 1) was clear and provided suitable growth of only M. furfur (large buttons in wells). The medium was not suitable forgrowth of the other species (small buttons), or it was turbid (Table 1); all nine formulations were adjusted to pH 7.0 (17). Because of that, only 41 M. furfur isolates were tested with RPMI 1640 medium no. 7 but all isolates were tested with Christensen's urea (Difco, Detroit, MI) supplemented with 0.1% Tween 80 and 0.5% Tween 40 (Sigma), pH 5.2, and by following CLSI guidelines (17).

View this table: [in this window] [in a new window]

TABLE 1. Different supplemented RPMI 1640 broths evaluated for susceptibility testing of Malassezia spp.a

Yeasts were grown on modified Dixon agar (3.6% malt extract [Oxoid, Basingstoke, United Kingdom], 0.6% peptone [Difco], 1% Tween 40, 2% desiccated ox bile, 0.2% glycerol, 0.2% oleic acid [all from Sigma]) for 72 h (32°C ± 2°C), and uniform suspensions were prepared with the aid of sterile swabs in sterile distilled water (0.04% Tween 80 [Sigma]). Inoculum suspensions (10⁶ CFU/ml) were adjusted by spectrophotometer (SP-850; Turner, Dubuque, IA) to an absorbance of either 1.0 (660-nm wavelength, M. globosa and M. restricta) or 0.425 to 0.435 (530-nm wavelength, other species). Prior inoculum sizes have ranged from 10³ to 10⁶ CFU/ml (9, 12, 13, 16, 20, 21). Although our inoculum density was higher than that recommended for other yeasts (10³ CFU/ml) (17), it provided suitable growth for all six species between 72 and 96 h. The inoculum preparation procedure yielded reproducible results (>92%, 0.5 to 6 x 10⁵ CFU/ml after dilution); the others had slightly lower (0.2 x 10⁵ CFU/ml) or higher (7 x 10⁵ CFU/ml) densities (viable colony counts).

Stock suspensions of voriconazole (Pfizer Pharmaceuticals, New York, N.Y.), itraconazole, and ketoconazole (Janssen Pharmaceuticals, Beerse, Belgium) were prepared in dimethyl sulfoxide; the final drug concentrations in each medium were 0.03 to 16 µg/ml. Microdilution trays were incubated at 32°C ± 2°C for 96 (M. globosa and M. restricta) and 72 h (other species). Azole MICs were the lowest drug concentrations that showed an optical density of 50% (Labsystems Multiskan, Franklin, Mo.; 550-nm filter) of that of the (drug-free) growth control.

Both on-scale and off-scale MICs were considered in agreement when results from the different testing days for each isolate and with each antifungal agent were within a 3-dilution range (17). The comparison of duplicate MICs obtained with the six reference strains and 10% of the 200 isolates evaluated with each antifungal agent indicated that MICs were reproducible (within 1 to 2 dilutions) (Table 2), including the consistently high MICs for M. globosa and M. restricta.

Excellent activity was demonstrated with the three azoles for M. furfur with RPMI medium (MIC₉₀s [MICs at which 90% of the isolates tested were inhibited], 0.125 to 0.5 µg/ml; results not included in Table 3) as previously reported (MIC₉₀s, 0.03 to 1 µg/ml) by using a similarly modified RPMI 1640 medium (21) and other methods (9, 12, 20). Results were comparable to those obtained with the urea broth (Table 3).

View this table: [in this window] [in a new window]

TABLE 3. In vitro susceptibilities of 200 Malassezia sp. isolates to three antifungal agents as determined by the modified urea and CLSI broth microdilution methodsa

In contrast to the numerous antifungal susceptibility profiles reported for other yeasts (5), few are available for the different Malassezia spp. Earlier data were for either M. furfur or Pityrosporum spp. (1, 6, 7, 14, 18, 19). Susceptibility to the three azoles was species dependent, with low MICs (<1 µg/ml) for most Malassezia spp. and high endpoints (MIC₉₀s, 1 to 8 µg/ml) for M. globosa and M. restricta (Table 3). Itraconazole MICs have been similar (0.8 to 6.3 µg/ml) to ours for these two species with the urea broth (16) and discrepant (<1 µg/ml) by other methods (12, 13, 20, 21). These contradictory results were obtained by using nonstandardized methodologies with either <10 isolates per species (12, 13, 16, 20, 21) or testing with a much lower inoculum (21) or by an agar dilution method (20). We evaluated 16 to 74 isolates of four of the six species and evaluated voriconazole for the first time with the urea broth. Unfortunately, the effect of testing variables on MICs, including their reproducibility, has not been evaluated as it has been for other yeasts (17). All of these factors could preclude a reliable comparison of MIC data, which a standardized method should clarify.

The urease method has identified the possible species azole activity dependency in our and a previous study (16); resistance detection is the most important goal of antifungal susceptibility testing. This fact further supports the importance of performing susceptibility testing of these isolates by a standardized method. The poor activity demonstrated by the three azoles against M. globosa and to a certain extent against M. restricta could be an important finding. M. globosa is the etiological agent of pityriasis versicolor, which has a high rate (60 to 80%) of recurrence (4, 10). Based on pharmacokinetics, pharmacodynamics, and in vitro correlations with clinical response in candidal infections, voriconazole MICs of 1 µg/ml (susceptibility breakpoint) have correlated with a clinical therapeutic response while voriconazole MICs of 4 µg/ml and itraconazole MICs of 1 µg/ml are indicators of a poor response to therapy (resistant breakpoints) with these two agents (2). Although the correlation between in vitro and in vivo results for Malassezia spp. has not been established for any antifungal agent, high azole MICs could also indicate a poor therapeutic response, as they have for Candida spp.

In conclusion, the optimum testing conditions for the Malassezia spp. evaluated were Christensen's urea broth with 0.1% Tween 80 and 0.5% Tween 40, stock inoculum suspensions adjusted to an optical density of either 0.425 to 0.435 (530 nm) or 1.0 (660 nm, M. globosa and M. restricta), and incubation times of 72 to 96 h. Collaborative studies are essential to investigate the interlaboratory reproducibility of our modified method.

 
This project was supported by Instituto Colombiano for Science and Technology (COLCIENCIAS) grant 1204-04-10175.

 
* Corresponding author. Mailing address: VCU Medical Center, Medical Mycology Research Laboratory, 1101 E. Marshal Street, Sanger Hall Room 7049, P.O. Box 980049, Richmond, VA 23298-0049. Phone: (804) 828-5743. Fax: (804) 828-3097. E-mail: avingrof{at}vcu.edu.

Top Abstract Text References

 

1
1. Ahn, K. J., and H. R. Ashbee. 1996. Determination of minimum inhibitory concentrations of several azole antifungals for Malassezia furfur. Ann. Dermatol. 8:187-194.
2
2. Clinical and Laboratory Standards Institute. 2006. Quality control minimal inhibitory concentration (MIC) limits for broth dilution and MIC interpretative breakpoints (M27-S2). Clinical and Laboratory Standards Institute, Wayne, Pa.
3
3. Crespo, V., and V. Delgado. 2002. Malassezia species in skin diseases. Curr. Opin. Infect. Dis. 15:133-142.[Medline]
4
4. Delescluse, J. 1990. Itraconazole in tinea versicolor: a review. J. Am. Acad. Dermatol. 23:551-554.[Medline]
5
5. Espinel-Ingroff, A., K. Boyle, and D. Sheenan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.[CrossRef][Medline]
6
6. Faergemann, J. 1984. In vitro and in vivo activities of ketoconazole and itraconazole against Pityrosporum orbiculare. Antimicrob. Agents Chemother. 26:773-774.[Abstract/Free Full Text]
7
7. Faergemann, J., and M. Borgers. 1990. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Dermato-venereol. 70:172-176.
8
8. Gaitanis, G., A. Velegraki, E. Frangoulis, A. Mitroussia, T. Tsigonia, A. Tzimogianni, A. Katsambas, and N. J. Legakis. 2002. Identification of Malassezia species from patient skin scales by PCR-RFLP. Clin. Microbiol. Infect. 8:162-173.[CrossRef][Medline]
9
9. Garau, M., M. Pereiro, Jr., and A. del Palacio. 2003. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob. Agents Chemother. 47:2342-2344.[Abstract/Free Full Text]
10
10. Gúeho, E., G. Midgley, and J. Guillot. 1996. The genus Malassezia with description of four new species. Antonie Leeuwenhoek 69:337-355.
11
11. Guillot, J., E. Gueho, M. Lesourd, G. Midgley, G. Chevrier, and B. Dupont. 1996. Identification of Malassezia species. A practical approach. J. Mycol. Med. 6:103-110.
12
12. Gupta, A. K., Y. Kohli, A. Li, J. Faergemann, and R. Summerbell. 2000. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br. J. Dermatol. 142:758-765.[CrossRef][Medline]
13
13. Hammer, K. A., C. F. Carson, and T. V. Riley. 2000. In vitro activities of ketoconazole, econazole, miconazole and Melaleuca alternifolia (tea tree) oil against Malassezia species. Antimicrob. Agents Chemother. 44:467-469.[Abstract/Free Full Text]
14
14. Marcon, M. J., D. E. Durrell, D. A. Powell, and W. J. Buesching. 1987. In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob. Agents Chemother. 31:951-953.[Abstract/Free Full Text]
15
15. Mayser, P., P. Haze, C. Papavassilis, M. Pickel, K. Gruender, and E. Guého. 1997. Differentiation of Malassezia species: selectivity of Cremophor EL, castor oil and ricinoleic acid for M. furfur. Br. J. Dermatol. 137:208-213.[CrossRef][Medline]
16
16. Nakamura, Y., R. Kano, T. Murai, S. Watanabe, and A. Hasegawa. 2000. Susceptibility testing of Malassezia species using the urea broth microdilution method. Antimicrob. Agents Chemother. 44:2185-2186.[Abstract/Free Full Text]
17
17. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18
18. Schmidt, A., and B. Rühl-Hörster. 1996. In vitro susceptibility of Malassezia furfur against azole compounds. Mycoses 39:309-312.[Medline]
19
19. Strippoli, V., A. Piacentini, F. D. D'Auria, and N. Simonetti. 1997. Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo. Infection 25:303-306.[CrossRef][Medline]
20
20. Sugita, T., M. Tajima, T. Ito, M. Sairo, M. Kodama, R. Tsuboi, and A. Nishikawa. 2005. Antifungal activities of tacrolimus and azole agents against eleven currently accepted Malassezia species. J. Clin. Microbiol. 43:2824-2829.[Abstract/Free Full Text]
21
21. Velegraki, A., E. C. Alexopoulos, S. Kritikou, and G. Gaitanis. 2004. Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest. J. Clin. Microbiol. 42:3589-3593.[Abstract/Free Full Text]

---

Journal of Clinical Microbiology, September 2006, p. 3429-3431, Vol. 44, No. 9
0095-1137/06/$08.00+0     doi:10.1128/JCM.00989-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rincón, S. Articles by Espinel-Ingroff, A. Search for Related Content PubMed PubMed Citation Articles by Rincón, S. Articles by Espinel-Ingroff, A.